Clinical Trial Search

Primary: The Primary Endpoint of This Study Will be 24 Hours VAS Pain Score at Rest — 4.1; 4.3; 3.3 score on a scale

Primary: Overall Survival (OS) — 15.5; 13.5 Months — p=0.0040

Primary: Change From Pulmonary Vascular Resistance (PVR) From Baseline at Week 24 — 417.2 dynes*sec/cm^5

Primary: Percentage Change From Baseline in LS-BMD by DXA — 5.52; 5.07; 5.73; 5.03 Percentage change

Primary: Number of Participants With Adverse Events — 6; 8; 0; 2 Participants

Primary: Percentage of Participants With at Least One Serious Treatment-Emergent Adverse Event (TEAE) — 20 percentage of participants

Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) From Day 1 Through Day 5 Post-vaccination — 9.1; 25.4; 51.8; 78.5 Percentage of participants

Primary: Patient-level CDR and Region-level PPV of rhPSMA7.3 (18F) PET for BCR of Prostate Cancer Using Histopathology or Imaging as a SoT — 54.1; 51.4; 51.6; 46.2 percentage

Primary: Specificity — 92.9; 93.8; 96.9 percentage

Primary: Composite Outcome of Symptomatic Deep Vein Thrombosis, Pulmonary Embolism, Other Venous Thromboembolism, Ischemic Stroke, Myocardial Infarction, Other Arterial…

Primary: Change in Seated Diastolic Blood Pressure Between AZM and Placebo — 3.9; -1.6 mmHg

Primary: Mean Score of the 6-point Modified Rankin Scale (mRS) at Visit 5 After Completion of the Course of Therapy for Both Arms — 1.098; 1.46 score on a scale

Primary: Western Ontario and McMaster University's Osteoarthritis Index (WOMAC) — 24.9; 22.4; 26.1; 22.3 score on a scale

Primary: Neutralizing Antibody Titers Against the SARS-CoV-2 Index Virus (Wuhan Wild Type Isolate) at 2 Weeks After Trial Vaccination — 1018.1; 1060.6; 1259.0; 1619.6 titer…

Primary: Percentage of Participants Who Were Biochemical Responders at Week 28 — 40.0; 14.3 percentage of participants — p=0.0003